HER-2/neu expression in ovarian clear cell carcinomas

2003 ◽  
Vol 13 (1) ◽  
pp. 28-31 ◽  
Author(s):  
H. Iwamoto ◽  
H. Fukasawa ◽  
T. Honda ◽  
S. Hirata ◽  
K. Hoshi
Keyword(s):  
Breast Carcinoma ◽  
Cell Carcinoma ◽  
San Francisco ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Metastatic Breast ◽  
Breast Carcinomas ◽  
Ovarian Clear Cell Carcinoma ◽  
Clinical Prognosis ◽  
Her 2

HER-2 /neu is a 185-kDa glycoprotein and a transmembrane receptor with tyrosine kinase activity. Its overexpression is observed in 25–30% of primary breast carcinomas and is associated with a poor clinical prognosis. Recently, the U.S. Food and Drug Administration and the Japanese Ministry of Health, Welfare, and Labor approved the use of trastuzumab (Herceptin, Genentech, South San Francisco, CA) for the treatment of patients with metastatic breast carcinomas overexpressing HER-2 /neu. Results of clinical trials with Herceptin suggest that it may prolong the survival of patients with advanced metastatic breast carcinoma. Relatively little is known concerning the relationship between HER-2 /neu status and ovarian clear cell carcinoma. If HER-2 /neu overexpression status were demonstrable in ovarian clear cell carcinoma and a clinical correlation between overexpression and prognosis could be established, a rationale for clinical use of Herceptin for this tumor could be established. Our aim was to evaluate HER-2 /neu status in ovarian clear cell carcinomas. Fifteen ovarian clear cell carcinoma cases were immunostained for HER-2 /neu using HercepTest (DAKO, Glostrup, Denmark). Overexpression of HER-2 /neu was detected in only one case. Unlike in breast carcinoma, HER-2 /neu overexpression appeared to be uncommon in ovarian clear cell carcinomas. Herceptin may thus target only a small proportion of ovarian clear cell carcinomas and be of limited clinical value for treatment of this carcinoma.

Hypoxia-inducible Factor-1α Suppression in Ovarian Clear-cell Carcinoma Cells by Silibinin Administration

2020 ◽  
Vol 40 (12) ◽  
pp. 6791-6798
Author(s):  
MARIKO MIYAZAWA ◽  
MASANORI YASUDA ◽  
MASAKI MIYAZAWA ◽  
NAOKI OGANE ◽  
TOMOMI KATOH ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Hypoxia Inducible Factor ◽  
Carcinoma Cells ◽  
Ovarian Clear Cell Carcinoma ◽  
Hypoxia Inducible Factor 1Α

scholarly journals Targeting FXYD2 by cardiac glycosides potently blocks tumor growth in ovarian clear cell carcinoma

Oncotarget ◽  
2016 ◽  
Vol 7 (39) ◽  
pp. 62925-62938 ◽  
Author(s):  
I-Ling Hsu ◽  
Cheng-Yang Chou ◽  
Yi-Ying Wu ◽  
Jia-En Wu ◽  
Chen-Hsien Liang ◽  
...  
Keyword(s):  
Tumor Growth ◽  
Cell Carcinoma ◽  
Cardiac Glycosides ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Ovarian Clear Cell Carcinoma

scholarly journals Mismatch repair deficiency is associated with specific morphologic features and frequent loss of ARID1A expression in ovarian clear cell carcinoma

2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Huijuan Ge ◽  
Yaoxin Xiao ◽  
Guangqi Qin ◽  
Yanzi Gu ◽  
Xu Cai ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Tumor Infiltrating Lymphocytes ◽  
Tissue Microarrays ◽  
Ovarian Clear Cell Carcinoma ◽  
Repair Deficiency ◽  
Ovarian Epithelial Carcinoma ◽  
Histological Characteristics ◽  
Infiltrating Lymphocytes

Abstract Background Ovarian clear cell carcinoma (OCCC) is the second subtype of ovarian epithelial carcinoma reported to be closely related to Lynch syndrome (LS). ARID1A mutation is an important pathogenetic mechanism in OCCC that leads to loss of ARID1A expression in approximately half of OCCCs. However, the correlation of MMR status and ARID1A deficiency is unclear. The current study aimed to identify the clinical and histopathological characteristics of OCCC associated with dMMR and to further explore the association between dMMR and ARID1A deficiency. Methods A cohort of 176 primary OCCC patients was enrolled and review included histological characteristics (nuclear atypia, necrosis, mitosis, stromal hyalinization, and background precursors) and host inflammatory response (tumor-infiltrating lymphocytes, peritumoral lymphocytes, intratumoral stromal inflammation and plasma cell infiltration). Immunohistochemical staining of MLH1, PMS2, MSH2, MSH6 and ARID1A was performed using tissue microarrays. Results dMMR was detected in 10/176 tumors (6 %), followed by MSH2/MSH6 (6/176), MLH1/PMS2 (3/176), and MSH6 (1/176). The average age of patients with dMMR was younger than that of patients with intact MMR (46 y vs. 53 y). Tumors with diffuse intratumoral stromal inflammation remained significantly associated after multivariate analysis. ARID1A expression was absent in 8 patients with dMMR (8/10), which is a significantly higher frequency than that observed in patients with intact MMR (80 % vs. 43.2 %). Conclusions Our study indicates that diffuse intratumoral stromal inflammation of OCCCs is associated with dMMR, with loss of MSH2/MSH6 expression being most frequent. dMMR is strongly associated with the loss of ARID1A expression in OCCC.

scholarly journals 250 Differing risk of ovarian clear cell carcinoma in Asian subpopulations

2020 ◽  
Author(s):  
S Chow ◽  
D Kapp ◽  
C Liao ◽  
A Mann ◽  
O Dorigo ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Ovarian Clear Cell Carcinoma
Sign in / Sign up

Export Citation Format

Share Document